Randomized, Double-blind, Placebo-controlled Trial of Nimodipine in Acute Ischemic Hemispheric Stroke


Phase N/A Results

Trial Description

To test the hypothesis that nimodipine improves functional outcome in acute ischemic hemispheric stroke.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Randomized, double-blind, multicenter, placebo-controlled trial of 350 patients.

Patient Involvement

Patients were randomized to receive nimodipine 120 mg/d PO or matching placebo for 21 days. All patients received neurological examinations on admission, days 1, 7 and 21, and at 3 and 12 months.


Type Measure Time Frame Safety Issue
Primary Rankin grade, neurological score, and mobility at 12 months.
Secondary Survival and domicile at 12 months.